Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$110.32 USD

110.32
858,848

+0.39 (0.35%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $110.30 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?

by Zacks Equity Research

Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.

Deciphera (DCPH) Rises 70% in the Past 6 Months: Here's Why

by Zacks Equity Research

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device

by Zacks Equity Research

Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.

Deciphera (DCPH) Issues Strategic & Corporate Outlook for 2023

by Zacks Equity Research

Deciphera (DCPH) provides a strategic outlook and planned corporate milestones for 2023. The company also posts preliminary fourth-quarter and 2022 revenues.

The Zacks Analyst Blog Highlights Amazon.com, Novartis, Philip Morris International, Automatic Data Processing and Live Nation Entertainment

by Zacks Equity Research

Amazon.com, Novartis, Philip Morris International, Automatic Data Processing and Live Nation Entertainment are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Amazon.com, Novartis & Philip Morris

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Novartis AG (NVS) and Philip Morris International Inc. (PM).

Kinjel Shah headshot

Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More

by Kinjel Shah

Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study.

Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid

by Zacks Equity Research

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, GSK, PFE Relieved on Zantac Win & Other Updates

by Kinjel Shah

A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.

Novartis' (NVS) PNH Candidate Achieves Study Objectives

by Zacks Equity Research

Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.

Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.

Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study

by Zacks Equity Research

Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.

Incyte (INCY) Outperforms YTD: Will the Momentum Continue?

by Zacks Equity Research

Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.

Novartis (NVS) Set to Advance Malaria Drug Into Phase III

by Zacks Equity Research

Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.

Novartis (NVS) Reportedly Looking to Sell Its Business Units

by Zacks Equity Research

Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.

Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines

by Zacks Equity Research

Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.

Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services

ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up

by Zacks Equity Research

ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022

Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.

Kinjel Shah headshot

Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod

by Kinjel Shah

Novartis (NVS) and Merck (MRK) announce Q3 results. FDA approves J&J's (JNJ) multiple myeloma candidate, Tecvayli.

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3

by Zacks Equity Research

Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.

Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research

Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.

What's in Store for Novartis (NVS) This Earnings Season?

by Zacks Equity Research

Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.

Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion

by Zacks Equity Research

Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.